

ImmunoPrecise Antibodies Ltd

12:03 09 Apr 2019

ImmunoPrecise and TetraGenetics extend alliance to discover therapeutic antibodies for autoimmune disease

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPAF) is extending its collaboration with TetraGenetics to focus on the discovery of therapeutic antibodies, the company announced Tuesday.

Victoria-based ImmunoPrecise is working with TetraGenetics to discover new human monoclonal antibodies against three undisclosed, therapeutically-relevant ion channels, it said in a statement.

Shares of ImmunoPrecise rose nearly 3% in Canada to C\$0.82 and were up nearly 6% to US\$0.62 in the US by midday Tuesday.

READ: ImmunoPrecise Antibodies forms new antibody discovery subsidiary Talem Therapeutics

TetraGenetics is a biopharmaceutical company developing novel therapeutics to treat autoimmune diseases. The partnership is ongoing since 2017, when TetraGenetics signed an agreement with ModiQuest, which was later acquired by ImmunoPrecise.

The Massachusetts-based company's unique capability to generate high concentrations of difficult-to-produce ion channel proteins is what originally caught the attention of ImmunoPrecise, according to Jennifer Bath, ImmunoPrecise's CEO.

"TetraGenetics will provide us with unique screening formulations which should be highly effective for antibody discovery with our proprietary libraries," said Bath. "We're look forward to a close collaboration with TetraGenetics and are excited by the potential of combining the two unique technologies."

A key feature of the partnership will be using ImmunoPrecise's customized phage library technology to enable deep mining of the company's patient library repertoire to identify rare and functional monoclonal antibodies and develop them as therapeutics.

"Combining TetraGenetics and ImmunoPrecise proprietary technologies is likely to lead to the discovery of novel therapeutic antibodies to previously intractable targets for a variety of unmet medical needs," said Ted Clark, chief scientific officer and founder of TetraGenetics.

ImmunoPrecise is concentrating on discovering the most relevant next-generation antibodies that it feels has the highest probability of succeeding through clinical trials.


Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Price: \$0.59

Market Cap: \$40.08 m

1 Year Share Price Graph



September 2018 March 2019 September 2019

Share Information

Code: IPA

Listing: TSX-V

52 week	High	Low
	0.98	0.5

Sector: Pharma & Biotech

Website: immunoprecise.com

Company Synopsis:

ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).